Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines emerging immunotherapies for multiple myeloma. Immunotherapy has been a large area of research in myeloma over the last 5 years and many novel agents have been discovered. ASH 2020 will see updates from numerous ongoing trials of BCMA-directed CAR T-cell therapy, as well as emerging data from next-generation CAR T-cells. Bispecific antibodies are also being investigated. An important recent development has been the identification of GPRC5D and FcRH5 as potential myeloma targets; results from early trials targeting these antigens will be seen at ASH. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть